Zelluna Immunotherapy presents data on its lead compound ZI-H04 at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Zelluna Immunotherapy, a biopharma company developing T-cell receptor guided adoptive cell therapy products for treatment of multiple solid cancers, announces it will present data on its lead TCR compound, ZI-H04 at a poster session.

Oslo, Norway, November 7, 2019 - Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for treatment of multiple solid cancers, today announces it will present data on its lead TCR compound, ZI-H04 at a poster session. The presentation will be at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), National Harbor, Maryland, US, November 6-10, 2019.

Jens-Peter Marschner, Chief Medical Officer, Zelluna Immunotherapy will deliver the poster presentation on ZI-H04, Zelluna’s lead candidate. The poster is entitled “ZI-H04 - A novel MHC class II restricted TCR based cellular therapy targeting hTERT to treat solid tumors”. ZI-H04 is an autologous, genetically engineered TCR-T, designed to target solid tumors with large patient populations. It will enter clinical development in autumn 2020. The details on ZI-H04 Jens-Peter will present include the scientific background of the product, the non-clinical rationale and the clinical design of the phase I/II study.

The poster presentation will be on Saturday, November 9, 2019, numbered abstract P368.

About Zelluna Immunotherapy

Zelluna Immunotherapy is a company developing transformative T cell receptor (TCR) based cellular immunotherapies for the treatment of solid cancers. The company is developing a unique portfolio of tumor specific TCR’s that target the MHC class II pathway to broadly engage the host immune system to provide a safe, efficient and durable clinical response. The company is developing therapies based on the effector functions of autologous T cells (TCR-T) and allogeneic NK cells (TCR-NK). Both of these platforms have their unique advantages and provides the opportunity to attack cancers from multiple angles and improve access to these advanced therapies to a large patient population. For more information, please visit www.zelluna.com.

MORE ON THIS TOPIC